Craig-Hallum Initiates Coverage on Onyx Pharmaceuticals (ONXX) with a Buy
More News related to ONXX
- Brean Murray Initiates Coverage on Onyx Pharmaceuticals (ONXX); Benefits Outweigh Risks, Two Potential Blockbusters
- Onyx Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
- Onyx Pharma (ONXX) Reaches Agreement with FDA on SPA for Phase 3 Trial of Carfilzomib
- Onyx Pharmaceuticals Announces Agreement with the FDA on a Special Protocol Assessment for Planned Phase 3 Carfilzomib Combination Trial in Relapsed Multiple Myeloma
- Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
Craig-Hallum initiates coverage on Onyx Pharmaceuticals (Nasdaq: ONXX) with a Buy. Price target $35.
To see more analyst ratings on ONXX Click Here.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally.
Related Categories
New CoverageStocks Mentioned
+0.59Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
